학술논문
Using Regional Sero-Epidemiology SARS-CoV-2 Anti-S Antibodies in the Dominican Republic to Inform Targeted Public Health Response
Document Type
article
Author
Beatris Mario Martin; Angela Cadavid Restrepo; Helen J. Mayfield; Cecilia Then Paulino; Micheal De St Aubin; William Duke; Petr Jarolim; Emily Zielinski Gutiérrez; Ronald Skewes Ramm; Devan Dumas; Salome Garnier; Marie Caroline Etienne; Farah Peña; Gabriela Abdalla; Beatriz Lopez; Lucia de la Cruz; Bernarda Henríquez; Margaret Baldwin; Benn Sartorius; Adam Kucharski; Eric James Nilles; Colleen L. Lau
Source
Tropical Medicine and Infectious Disease, Vol 8, Iss 11, p 493 (2023)
Subject
Language
English
ISSN
2414-6366
Abstract
Incidence of COVID-19 has been associated with sociodemographic factors. We investigated variations in SARS-CoV-2 seroprevalence at sub-national levels in the Dominican Republic and assessed potential factors influencing variation in regional-level seroprevalence. Data were collected in a three-stage cross-sectional national serosurvey from June to October 2021. Seroprevalence of antibodies against the SARS-CoV-2 spike protein (anti-S) was estimated and adjusted for selection probability, age, and sex. Multilevel logistic regression was used to estimate the effect of covariates on seropositivity for anti-S and correlates of 80% protection (PT80) against symptomatic infection for the ancestral and Delta strains. A total of 6683 participants from 134 clusters in all 10 regions were enrolled. Anti-S, PT80 for the ancestral and Delta strains odds ratio varied across regions, Enriquillo presented significant higher odds for all outcomes compared with Yuma. Compared to being unvaccinated, receiving ≥2 doses of COVID-19 vaccine was associated with a significantly higher odds of anti-S positivity (OR 85.94, [10.95–674.33]) and PT80 for the ancestral (OR 4.78, [2.15–10.62]) and Delta strains (OR 3.08, [1.57–9.65]) nationally and also for each region. Our results can help inform regional-level public health response, such as strategies to increase vaccination coverage in areas with low population immunity against currently circulating strains.